Skycorp Solar Group Limited(PN)Earnings, Financials & Key Ratios

-- Remains on track to release interim NF1 data update in Q4 2026 -- -- Additional dose levels and longer treatment period added -- MIAMI, June 16, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, today announced it has amended the clinical study protocol for the Phase 1/1b trial of PAS-004 in neurofibromatosis type 1 (NF1) patients with symptomatic inoperable, incompletely resected, or recurrent plexiform neurofibroma (PN). The amendments include an update to the dose escalation part of the study (Part A) to allow for the enrollment of additional participants at two additional higher dose levels (24mg and 32mg), the ability to backfill completed dose cohorts (4mg, 8mg, 12mg and 18mg) with up to two participants, and the evaluation of intermediate dose levels.

NINGBO, China, June 15, 2026 (GLOBE NEWSWIRE) -- PN Smart Energy Limited (“PN Smart” or the “Company”) (NASDAQ: PN), a global independent power provider (IPP) focused on the development of clean power stations, critical energy materials, and intelligent energy infrastructure, today announced its official name change of Skycorp Solar Group Limited to PN Smart Energy Limited effective June 12, 2026. The name change has been approved by the Company‘s shareholders at an extraordinary general meeting held on June 10, 2026, and became legally effective upon the Company's receipt of the Certificate of Incorporation on Change of Name from the Registrar of Companies of the Cayman Islands on June 12, 2026.